切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2013, Vol. 01 ›› Issue (01) : 20 -25. doi: 10.3877/cma.j.issn.2095-5820.2013.01.005

综述

循环微小RNA检测的临床应用研究进展
郁佳佳1, 鞠少卿2,()   
  1. 1.215006 苏州大学附属第一医院检验科
    2.南通大学附属医院 医学检验中心 南通大学公共卫生学院 外科综合实验室
  • 收稿日期:2013-07-25 出版日期:2013-11-28
  • 通信作者: 鞠少卿
  • 基金资助:
    国家自然科学基金资助项目(81271920)江苏省“科教兴卫工程”医学创新团队项目资助课题(LJ201133)

Progress in clinical applications of circulating miRNAs

Jiajia Yu1, Shaoqing Ju2,()   

  1. 1.Department of Clinical Laboratory, First Hospital Affiliated of Suzhou University, Suzhou 215006, China
    2.Laboratory Medicine Center, Affiliated Hospital of Nantong University,Surgical Comprehensive Laboratory, School of Public Health Nantong University, Nantong 226001, China
  • Received:2013-07-25 Published:2013-11-28
  • Corresponding author: Shaoqing Ju
引用本文:

郁佳佳, 鞠少卿. 循环微小RNA检测的临床应用研究进展[J/OL]. 中华临床实验室管理电子杂志, 2013, 01(01): 20-25.

Jiajia Yu, Shaoqing Ju. Progress in clinical applications of circulating miRNAs[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2013, 01(01): 20-25.

肿瘤是导致人类死亡的主要原因之一,找到具有早期诊断意义的肿瘤标志对恶性肿瘤治疗至关重要。微小RNA(MicroRNAs,miRNAs)作为致癌或抑癌基因,参与细胞增殖、分化、凋亡以及各种免疫反应,其可以稳定地存在于血清和血浆等多种体液中,其特定的表达谱与多种肿瘤的发生密切相关,因此有望成为肿瘤诊断、分型、疗效监测以及预后判断的生物标志物。在此,对循环miRNAs来源、检测方法以及在各种肿瘤中的临床应用综述如下。

Cancer is one of the leading cause of death in the world. Development of minimally invasive biomarkers for early detection of cancer is urgently needed to reduce the morbidity and mortality.MiRNAs may act as oncogenes or tumour-suppressors, participating in a series of biological activities including cell proliferation, differentiation, apoptosis and immune response. Recent studies have indicated that miRNAs take a stable, reproducible, cell-free form in the body fluid, and their unique expression patterns are correlated with certain human diseases, including various types of cancer. Circulating miRNAs enjoys the potential as blood-based fingerprints for cancer diagnosis, classification, therapeutic decisions, and prognosis.This article focuses on the origin, detecting method of circulating miRNAs and their potential as minimally invasive biomarkers for tumor malignancy.

1
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J].Cell, 1993,75:843-854.
2
Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans[J]. Nature,2000,403:901-906.
3
Bushati N, Cohen SM. MicroRNA functions[J]. Annu Rev Cell Dev Biol, 2007, 23:175-205.
4
Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma[J]. Br J Haematol, 2008,141:672-675.
5
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J].Cell Res, 2008,18:997-1006.
6
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105:10513-10518.
7
Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers[J]. Med Res Rev,2012,32:326-348.
8
Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells[J]. Nat Cell Biol, 2007, 9:654-659.
9
Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform[J]. Gynecol Oncol, 2009,112:55-59.
10
Sun G, Wu X, Wang J, et al. A bias-reducing strategy in profiling small RNAs using Solexa[J]. RNA, 2011,17:2256-2262.
11
Beuvink I, Kolb FA, Budach W, et al. A novel microarray approach reveals new tissue-specific signatures of known and predicted mammalian microRNAs[J]. Nucleic Acids Res, 2007,35:e52.
12
Lawrie CH, Soneji S, Marafioti T, et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma[J]. Int J Cancer,2007,121:1156-1161.
13
Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening[J]. Gut, 2009,58:1375-381.
14
McDonald JS, Milosevic D, Reddi HV, et al. Analysis of circulating microRNA: preanalytical and analytical challenges[J]. Clin Chem,2011,57:833-840.
15
Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease[J]. Int J Cancer, 2009,124:367-375.
16
Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma[J].J Transl Med, 2012,10:55.
17
Flamant S, Ritchie W, Guilhot J, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia[J].Haematologica, 2010,95:1325-1333.
18
Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma[J].Br J Cancer, 2012, 107:1987-1996.
19
Huang JJ, Yu J, Li JY, et al. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma[J].Med Oncol, 2012,29:2402-2408.
20
Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders[J]. Blood Cancer J, 2012,2:e53.
21
Wang Q, Huang Z, Ni S, et al. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer[J]. PLoS One,2012,7:e44398.
22
Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer[J]. Int J Cancer, 2010,127:118-126.
23
Kanaan Z, Roberts H, Eichenberger MR, et al. A Plasma MicroRNA Panel for Detection of Colorectal Adenomas[J]. Ann Surg, 2013,258:400-408.
24
Toiyama Y, Hur K, Tanaka K, et al, Serum miR-200c Is a Novel Prognostic and Metastasis-Predictive Biomarker in Patients With Colorectal Cancer[J]. Ann Surg, 2013, [Epub ahead of print].
25
Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer[J]. J Clin Oncol, 2010,28:1721-1726.
26
Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs(miRNA) in serum of patients with prostate cancer[J]. Urology,2011,77:1265 e1269-1216.
27
Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer[J]. Int J Cancer,2011,128:608-616.
28
Schrauder MG, Strick R, Schulz-Wendtland R, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection[J]. PLoS One, 2012,7:e29770.
29
Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer[J]. Clin Chem,2011,57:84-91.
30
Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J]. J Hepatol,2012,56:167-175.
31
Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma[J]. Cancer Res, 2010, 70:9798-97807.
32
Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol,2011, 29:4781-4788.
33
Yu J, Wang Y, Dong R, et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion[J]. J Cancer Res Clin Oncol, 2012, 138:671-674.
34
Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer[J]. Cancer Res, 2007,67:8699-8707.
35
Kan CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer[J]. BMC Cancer, 2012,12:627.
36
Liu R, Chen X, Du Y, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer[J]. Clin Chem, 2012,58:610-618.
37
Long G, Wang F, Duan Q, et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction[J]. Int J Biol Sci, 2012,8:811-818.
38
Jaguszewski M, Osipova J, Ghadri JR, et al. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction[J]. Eur Heart J, 2013. [Epub ahead of print].
39
Zhang Q, Kandic I, Faughnan ME, et al. Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: a potential new biomarker[J]. Biomarkers, 2013,18:23-29.
40
Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer[J]. Urol Oncol, 2010,28:655-661.
41
Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery,characterization, and clinical utility for oral cancer detection[J]. Clin Cancer Res, 2009,15:5473-5477.
42
Chim SS, Shing TK, Hung EC, et al. Detection and characterization of placental microRNAs in maternal plasma[J]. Clin Chem, 2008,54:482-490.
43
Zhao Z, Zhao Q, Warrick J, et al. Circulating microRNA miR-323-3p as a biomarker of ectopic pregnancy[J]. Clin Chem, 2012,58:896-905.
[1] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[2] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[7] 赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[8] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[9] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[10] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[13] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[14] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[15] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
阅读次数
全文


摘要